Search

Valeria R Fantin

from Portola Valley, CA
Age ~54
Get Report
Also known as:
Valeria Rosa Fantin
Connected to:
Carol M Fantin, 83Amedeo A Fantini, 102Andrea Fantini, 37Dana R Fantini, 56Debora A Fantini, 66Dominick A Fantini, 95Lisa L Fantini, 57Mario Fantini, 97Riccardo Fantini, 54Thomas P Fantini, 69

Valeria Fantin Phones & Addresses

  • Portola Valley, CA
  • San Mateo, CA
  • Burlingame, CA
  • La Jolla, CA
  • 195 Binney St, Cambridge, MA 02142 (617) 945-5752
  • 195 Binney St APT 4515, Cambridge, MA 02142 (617) 945-5752
  • Boston, MA
  • Lebanon, NH

Work

Company: Pfizer Oct 2011 Address: La Jolla Position: Vp, tumor cell biology

Education

Degree: Post-doc School / High School: Harvard Medical School 2000 to 2004

Industries

Pharmaceuticals

Resumes

Resumes

Valeria Fantin Photo 1

Chief Strategy Officer

View page
Location:
Menlo Park, CA
Industry:
Pharmaceuticals
Work:
Pfizer - La Jolla since Oct 2011
VP, Tumor Cell Biology
Agios Pharmaceuticals Jan 2009 - Oct 2011
Senior Director, Molecular Oncology
ARIAD Pharmaceuticals May 2008 - Dec 2008
Principal Scientist
Merck Aug 2004 - May 2008
Senior Scientist
Education:
Harvard Medical School 2000 - 2004
Post-doc Dartmouth Medical School 1996 - 1999
PhD

Publications

Us Patents

Compounds Regulating Cell Proliferation And Differentiation

View page
US Patent:
20040097408, May 20, 2004
Filed:
Jul 3, 2003
Appl. No.:
10/613762
Inventors:
Philip Leder - Chestnut Hill MA, US
Valeria Fantin - Boston MA, US
International Classification:
A61K038/00
US Classification:
514/002000
Abstract:
The invention provides compounds and methods for normalizing the proliferation and/or modulating differentiation and/or inducing the cell death of cells. In a preferred embodiment, the invention provides methods for inhibiting proliferation of hyper-proliferative cells, comprising contacting the cells with a composition comprising a growth inhibiting amount of one or more compounds selected from the group consisting of E20 (ID 141525); F12 (ID 120590); F16 (ID 274873); H10 (ID 120670); J6 (ID 120856); N12 (ID 215015); L4 (ID 121113); B 15 (ID 217496) and QR, or derivatives or analogs thereof, or pharmaceutically acceptable salts thereof.

Methods For Predicting Treatment Response Based On The Expression Profiles Of Protein And Transcription Biomarkers

View page
US Patent:
20090304594, Dec 10, 2009
Filed:
Dec 1, 2006
Appl. No.:
12/086102
Inventors:
Valeria R. Fantin - Cambridge MA, US
Jacqueline W. Pierce - Wellesley MA, US
Andrey Loboda - Philadelphia PA, US
International Classification:
A61K 49/00
G01N 33/53
A61P 35/00
US Classification:
424 92, 435 71
Abstract:
The invention disclosed herein describes novel biomarkers useful for risk assessment, screening, prognosis and selection and monitoring of therapy for HDAC mediated cell proliferative disorders. In particular, the invention provides the identities of three particular proteins whose expression patterns are strongly predictive of a particular patient's treatment outcome, e.g., non-responsiveness to SAHA. The expression profile, or pattern, whether embodied in nucleic acid expression, protein expression, or other expression formats will find use in identifying and selecting patients afflicted with a particular HDAC mediated cancer who are likely to be non-responsive to SAHA-based therapy and thus candidates for other treatments.

Methods And Compositions For Cell-Proliferation-Related Disorders

View page
US Patent:
20120121515, May 17, 2012
Filed:
Mar 12, 2010
Appl. No.:
13/256396
Inventors:
Lenny Dang - Boston MA, US
Valeria Fantin - La Jolla CA, US
Stefan Gross - Brookline MA, US
Hyun Gyung Jang - Arlington MA, US
Shengfang Jin - Newton MA, US
Francesco G. Salituro - Marlborough MA, US
Jeffrey O. Saunders - Concord MA, US
Shinsan Su - Newton MA, US
Katharine Yen - Wellesley MA, US
International Classification:
A61K 49/06
C12Q 1/32
G01N 33/573
C12Q 1/42
A61K 49/00
C12Q 1/68
US Classification:
424 93, 424 91, 435 612, 435 74, 435 21, 435 26
Abstract:
Methods of treating and evaluating subjects having neoactive mutants are described herein.

Methods And Compositons For Cell-Proliferation-Related Disorders

View page
US Patent:
20130183281, Jul 18, 2013
Filed:
Apr 20, 2012
Appl. No.:
13/452136
Inventors:
Shin-San Michael Su - Newton MA, US
Lenny Dang - Boston MA, US
Stefan Gross - Brookline MA, US
Shengfang Jin - Newton MA, US
Valeria Fantin - La Jolla CA, US
International Classification:
A61K 38/44
A61K 31/713
A61K 31/375
A61K 38/06
A61K 31/05
A61K 31/522
A61K 31/015
A61K 31/355
A61K 31/122
A61K 31/7004
A61K 31/381
US Classification:
424 944, 514 23, 514 44 A, 514474, 514 192, 424 941, 514440, 51426333, 514763, 514458, 514690, 514733
Abstract:
Methods of treating and evaluating subjects having neoactive mutants of IDH (e.g., IDH1 or IDH2).

Methods Of Identifying A Candidate Compound

View page
US Patent:
20130197106, Aug 1, 2013
Filed:
Mar 31, 2011
Appl. No.:
13/638881
Inventors:
Valeria Fantin - La Jolla CA, US
Shin-San Michael Su - Newton MA, US
Assignee:
AGIOS PHARMACEUTICALS, INC - Cambridge MA
International Classification:
C12Q 1/32
US Classification:
514789, 435 32, 435 26, 506 10
Abstract:
The invention relates to methods identifying compounds for the treatment of cell proliferation-related disorders, e.g., proliferative disorders such as cancer.

Cd73 Inhibitors

View page
US Patent:
20220411459, Dec 29, 2022
Filed:
Oct 29, 2020
Appl. No.:
17/771711
Inventors:
- South San Francisco CA, US
John EKSTEROWICZ - Burlingame CA, US
Valeria R. FANTIN - Burlingame CA, US
Daqing SUN - Foster City CA, US
Qiuping YE - Foster City CA, US
Jared MOORE - San Rafael CA, US
Tatiana ZAVOROTINSKAYA - Moraga CA, US
Brian R. BLANK - Daly City CA, US
Yosup REW - Foster City CA, US
Kejia WU - South San Francisco CA, US
Liusheng ZHU - Foster City CA, US
Johnny PHAM - San Bruno CA, US
Hiroyuki KAWAI - Pacifica CA, US
Chien-Hung YEH - San Bruno CA, US
International Classification:
C07H 19/23
A61K 45/06
Abstract:
Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.

Cd73 Inhibitors

View page
US Patent:
20220331343, Oct 20, 2022
Filed:
Jul 15, 2020
Appl. No.:
17/626731
Inventors:
- South San Francisco CA, US
John EKSTEROWICZ - Burlingame CA, US
Valeria R. FANTIN - Burlingame CA, US
Daqing SUN - Foster City CA, US
Qiuping YE - Foster City CA, US
Jared MOORE - San Rafael CA, US
Tatiana ZAVOROTINSKAYA - Moraga CA, US
Brian R. BLANK - Daly City CA, US
Hiroyuki KAWAI - Pacifica CA, US
Chien-Hung YEH - San Bruno CA, US
Yosup REW - Foster City CA, US
Kejia WU - South San Francisco CA, US
Johnny PHAM - San Bruno CA, US
International Classification:
A61K 31/675
C07F 9/6561
A61P 35/00
A61K 45/06
Abstract:
Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.

Cd73 Inhibitors

View page
US Patent:
20220259253, Aug 18, 2022
Filed:
Apr 18, 2022
Appl. No.:
17/722513
Inventors:
- South San Francisco CA, US
John EKSTEROWICZ - Burlingame CA, US
Valeria R. FANTIN - Burlingame CA, US
Erica L. JACKSON - Burlingame CA, US
Daqing SUN - Foster City CA, US
Qiuping YE - Foster City CA, US
Jared MOORE - San Rafael CA, US
Tatiana ZAVOROTINSKAYA - Moraga CA, US
International Classification:
C07H 19/23
A61P 35/00
A61K 31/706
C07H 19/056
A61K 31/7064
Abstract:
Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.
Control profile
Valeria R Fantin from Portola Valley, CA, age ~54 Get Report